Northern Trust’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Northern Trust’s Portfolio TLIS Stock Details TLIS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,857	Closed	-$13.4K	–	4534
2023 Q2	$13.4K	Hold	1,857	–	–	﹤0.01%	4457
2023 Q1	$13.7K	Hold	1,857	–	–	﹤0.01%	4493
2022 Q4	$12.4K	Hold	1,857	–	–	﹤0.01%	4548
2022 Q3	$19K	Hold	1,857	–	–	﹤0.01%	4558
2022 Q2	$22K	Sell	1,857 -6,394	-77%	-$101K	﹤0.01%	4612
2022 Q1	$175K	Sell	8,251 -258	-3%	-$8.93K	﹤0.01%	4175
2021 Q4	$511K	Sell	8,509 -199	-2%	-$14.9K	﹤0.01%	3809
2021 Q3	$817K	Sell	8,708 -546	-6%	-$72.8K	﹤0.01%	3613
2021 Q2	$1.53M	Buy	9,254 +22	+0.2%	+$3.74K	﹤0.01%	3431
2021 Q1	$1.78M	Buy	+9,232	New	+$2.3M	﹤0.01%	3304

Other funds holding TLIS

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Northern Trust's TLIS Position: Q3 2023 in Review

Northern Trust sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q3 2023, closing a stake of 1,857 shares — an estimated $13.4K sold.

Northern Trust first reported a position in TLIS in Q1 2021 and held it in 10 quarters. The position peaked at $1.78M in Q1 2021. 19 funds tracked by Wall St. Rank hold TLIS as of Q3 2023.

Northern Trust reported no remaining Talis Biomedical Corporation Common Stock position as of Q3 2023 after selling out during the quarter.
Northern Trust sold 1,857 Talis Biomedical Corporation Common Stock shares in Q3 2023, an estimated $13.4K.
Northern Trust first reported a position in Talis Biomedical Corporation Common Stock in Q1 2021 and held it in 10 quarters.
Northern Trust's Talis Biomedical Corporation Common Stock position peaked at $1.78M in Q1 2021.
19 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q3 2023.

Based on Northern Trust's 13F filing for Q3 2023, filed 13 Nov 2023.